Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Chunshuen Au

Physician Assistant Flushing, NY Physician Assistant

NPI 1790043859 CMS profile 10528404

143-55 37Th Avenue, 1St Floor, Flushing, NY 11354

Open in the dashboard

General payments

$11,144

442 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Chunshuen Au of Flushing, NY is reported in the CMS Open Payments database as having received $11,144 across 442 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,525 103
2024 General $2,966 109
2023 General $2,098 78
2022 General $2,035 75
2021 General $1,519 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chunshuen Au
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Chunshuen Au were reported at $2,525. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Chunshuen Au Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,519 $132 $37–$438 $132
2022 $2,035 $155 $48–$522 $149
2023 $2,098 $167 $52–$557 $160
2024 $2,966 $178 $55–$600 $164
2025 $2,525 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $3,034 101 payments
  2. Gilead Sciences, Inc. $2,207 65 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,475 61 payments
  4. Novo Nordisk Inc $1,196 60 payments
  5. GlaxoSmithKline, LLC. $750 40 payments
  6. Amgen Inc. $634 28 payments
  7. Lilly USA, LLC $464 21 payments
  8. Amarin Pharma Inc. $298 14 payments
  9. Esperion Therapeutics, Inc. $289 14 payments
  10. AbbVie, Inc. $220 10 payments
  11. Other $575 28 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,144 442 payments
Products named General payments · program years 2021–2025
  1. BREZTRI $2,048 58 payments
  2. Ozempic $1,054 53 payments
  3. RYBELSUS $931 48 payments
  4. TRELEGY ELLIPTA $659 35 payments
  5. STIOLTO RESPIMAT $565 27 payments
  6. FARXIGA $497 24 payments
  7. AIRSUPRA $377 14 payments
  8. Vemlidy $374 3 payments
  9. JARDIANCE Diabetes $370 13 payments
  10. JARDIANCE Diabetes $334 16 payments
  11. Other $4,047 180 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 192 drugs

Part D claims

19,489

Median for Physician Assistant: 241

Drug cost

$2,908,896

Median for Physician Assistant: $4,110

Branded share of claims

27.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Epolamine Generic 609 $535,914
Vascepa Icosapent Ethyl Brand 1,088 $459,905
Restasis Cyclosporine Brand 269 $191,949
Jardiance Empagliflozin Brand 161 $135,140
Vemlidy Tenofovir Alafenamide Brand 73 $102,674
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 145 $98,934
Farxiga Dapagliflozin Propanediol Brand 116 $97,690
Omeprazole-Sodium Bicarbonate Omeprazole/Sodium Bicarbonate Brand 38 $71,026
Eliquis Apixaban Brand 104 $68,357
Nexium Esomeprazole Magnesium Brand 219 $67,162

The 10 drugs with the highest cost, of 192 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
  • AstraZeneca Pharmaceuticals LP $604
$604 145 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $215
  • Lilly USA, LLC $111
$326 161 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $300
$300 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $227
$227 27 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $200
$200 116 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

442 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record